Prescriber  ||| S:0 E:11 ||| JJ
continuity  ||| S:11 E:22 ||| NN
and  ||| S:22 E:26 ||| CC
medication  ||| S:26 E:37 ||| NN
adherence  ||| S:37 E:47 ||| NN
for  ||| S:47 E:51 ||| IN
complex  ||| S:51 E:59 ||| JJ
patients  ||| S:59 E:68 ||| NNS
Medication  ||| S:68 E:79 ||| JJ
adherence  ||| S:79 E:89 ||| NN
is  ||| S:89 E:92 ||| VBZ
a  ||| S:92 E:94 ||| DT
critical  ||| S:94 E:103 ||| JJ
aspect  ||| S:103 E:110 ||| NN
of  ||| S:110 E:113 ||| IN
managing  ||| S:113 E:122 ||| VBG
cardiometabolic  ||| S:122 E:138 ||| JJ
conditions ||| S:138 E:148 ||| NNS
,  ||| S:148 E:150 ||| ,
including  ||| S:150 E:160 ||| VBG
diabetes ||| S:160 E:168 ||| NN
,  ||| S:168 E:170 ||| ,
hypertension ||| S:170 E:182 ||| NN
,  ||| S:182 E:184 ||| ,
dyslipidemia ||| S:184 E:196 ||| NN
,  ||| S:196 E:198 ||| ,
and  ||| S:198 E:202 ||| CC
heart  ||| S:202 E:208 ||| NN
failure ||| S:208 E:215 ||| NN
.  ||| S:215 E:217 ||| .
Patients  ||| S:217 E:226 ||| NNS
who  ||| S:226 E:230 ||| WP
have  ||| S:230 E:235 ||| VBP
multiple  ||| S:235 E:244 ||| JJ
cardiometabolic  ||| S:244 E:260 ||| JJ
conditions  ||| S:260 E:271 ||| NNS
and  ||| S:271 E:275 ||| CC
multiple  ||| S:275 E:284 ||| JJ
prescribers  ||| S:284 E:296 ||| NN
may  ||| S:296 E:300 ||| MD
be  ||| S:300 E:303 ||| VB
at  ||| S:303 E:306 ||| IN
increased  ||| S:306 E:316 ||| JJ
risk  ||| S:316 E:321 ||| NN
for  ||| S:321 E:325 ||| IN
nonadherence ||| S:325 E:337 ||| NN
.  ||| S:337 E:339 ||| .
The  ||| S:339 E:343 ||| DT
purpose  ||| S:343 E:351 ||| NN
of  ||| S:351 E:354 ||| IN
this  ||| S:354 E:359 ||| DT
study  ||| S:359 E:365 ||| NN
was  ||| S:365 E:369 ||| VBD
to  ||| S:369 E:372 ||| TO
examine  ||| S:372 E:380 ||| VB
the  ||| S:380 E:384 ||| DT
relationship  ||| S:384 E:397 ||| NN
between  ||| S:397 E:405 ||| IN
number  ||| S:405 E:412 ||| NN
of  ||| S:412 E:415 ||| IN
prescribers ||| S:415 E:426 ||| NN
,  ||| S:426 E:428 ||| ,
number  ||| S:428 E:435 ||| NN
of  ||| S:435 E:438 ||| IN
conditions ||| S:438 E:448 ||| NNS
,  ||| S:448 E:450 ||| ,
and  ||| S:450 E:454 ||| CC
refill  ||| S:454 E:461 ||| JJ
adherence  ||| S:461 E:471 ||| NN
to  ||| S:471 E:474 ||| TO
oral  ||| S:474 E:479 ||| JJ
medications  ||| S:479 E:491 ||| NN
to  ||| S:491 E:494 ||| TO
treat  ||| S:494 E:500 ||| VB
cardiometabolic  ||| S:500 E:516 ||| JJ
conditions ||| S:516 E:526 ||| NNS
.  ||| S:526 E:528 ||| .
In  ||| S:528 E:531 ||| IN
this  ||| S:531 E:536 ||| DT
retrospective  ||| S:536 E:550 ||| JJ
cohort  ||| S:550 E:557 ||| JJ
study ||| S:557 E:562 ||| NN
,  ||| S:562 E:564 ||| ,
7933  ||| S:564 E:569 ||| CD
veterans  ||| S:569 E:578 ||| NNS
were  ||| S:578 E:583 ||| VBD
identified  ||| S:583 E:594 ||| VBN
with  ||| S:594 E:599 ||| IN
1  ||| S:599 E:601 ||| CD
to  ||| S:601 E:604 ||| TO
4  ||| S:604 E:606 ||| CD
cardiometabolic  ||| S:606 E:622 ||| CD
conditions ||| S:622 E:632 ||| NNS
.  ||| S:632 E:634 ||| .
Refill  ||| S:634 E:641 ||| JJ
adherence  ||| S:641 E:651 ||| NN
to  ||| S:651 E:654 ||| TO
oral  ||| S:654 E:659 ||| JJ
medications  ||| S:659 E:671 ||| NN
for  ||| S:671 E:675 ||| IN
diabetes ||| S:675 E:683 ||| NN
,  ||| S:683 E:685 ||| ,
hypertension ||| S:685 E:697 ||| NN
,  ||| S:697 E:699 ||| ,
and  ||| S:699 E:703 ||| CC
dyslipidemia  ||| S:703 E:716 ||| NNS
was  ||| S:716 E:720 ||| VBD
measured  ||| S:720 E:729 ||| VBN
using  ||| S:729 E:735 ||| VBG
an  ||| S:735 E:738 ||| DT
administrative  ||| S:738 E:753 ||| JJ
claims-based  ||| S:753 E:766 ||| JJ
continuous  ||| S:766 E:777 ||| JJ
multiple-interval  ||| S:777 E:795 ||| JJ
gap  ||| S:795 E:799 ||| NN
( ||| S:799 E:800 ||| -LRB-
CMG ||| S:800 E:803 ||| NNP
)  ||| S:803 E:805 ||| -RRB-
that  ||| S:805 E:810 ||| WDT
estimates  ||| S:810 E:820 ||| VBZ
the  ||| S:820 E:824 ||| DT
percentage  ||| S:824 E:835 ||| NN
of  ||| S:835 E:838 ||| IN
days  ||| S:838 E:843 ||| NNS
a  ||| S:843 E:845 ||| DT
patient  ||| S:845 E:853 ||| NN
did  ||| S:853 E:857 ||| VBD
not  ||| S:857 E:861 ||| RB
possess  ||| S:861 E:869 ||| VB
medication ||| S:869 E:879 ||| NN
.  ||| S:879 E:881 ||| .
We  ||| S:881 E:884 ||| PRP
dichotomized  ||| S:884 E:897 ||| VBP
refill  ||| S:897 E:904 ||| JJ
adherence  ||| S:904 E:914 ||| NN
for  ||| S:914 E:918 ||| IN
each  ||| S:918 E:923 ||| DT
condition  ||| S:923 E:933 ||| NN
as  ||| S:933 E:936 ||| IN
a  ||| S:936 E:938 ||| DT
CMG  ||| S:938 E:942 ||| NNP
≤20 ||| S:942 E:945 ||| NNP
%  ||| S:945 E:947 ||| NN
for  ||| S:947 E:951 ||| IN
each  ||| S:951 E:956 ||| DT
year  ||| S:956 E:961 ||| NN
of  ||| S:961 E:964 ||| IN
analysis ||| S:964 E:972 ||| NN
.  ||| S:972 E:974 ||| .
Condition-specific  ||| S:974 E:993 ||| JJ
logistic  ||| S:993 E:1002 ||| JJ
regression  ||| S:1002 E:1013 ||| JJ
models  ||| S:1013 E:1020 ||| NNS
estimated  ||| S:1020 E:1030 ||| VBD
the  ||| S:1030 E:1034 ||| DT
relationship  ||| S:1034 E:1047 ||| NN
between  ||| S:1047 E:1055 ||| IN
refill  ||| S:1055 E:1062 ||| JJ
adherence  ||| S:1062 E:1072 ||| NN
and  ||| S:1072 E:1076 ||| CC
number  ||| S:1076 E:1083 ||| NN
of  ||| S:1083 E:1086 ||| IN
cardiometabolic  ||| S:1086 E:1102 ||| JJ
conditions  ||| S:1102 E:1113 ||| NNS
and  ||| S:1113 E:1117 ||| CC
number  ||| S:1117 E:1124 ||| NN
of  ||| S:1124 E:1127 ||| IN
prescribers ||| S:1127 E:1138 ||| NN
,  ||| S:1138 E:1140 ||| ,
controlling  ||| S:1140 E:1152 ||| VBG
for  ||| S:1152 E:1156 ||| IN
demographic  ||| S:1156 E:1168 ||| JJ
characteristics ||| S:1168 E:1183 ||| NNS
,  ||| S:1183 E:1185 ||| ,
other  ||| S:1185 E:1191 ||| JJ
comorbidities ||| S:1191 E:1204 ||| NN
,  ||| S:1204 E:1206 ||| ,
and  ||| S:1206 E:1210 ||| CC
a  ||| S:1210 E:1212 ||| DT
count  ||| S:1212 E:1218 ||| NN
of  ||| S:1218 E:1221 ||| IN
cardiometabolic  ||| S:1221 E:1237 ||| JJ
drug  ||| S:1237 E:1242 ||| NN
classes  ||| S:1242 E:1250 ||| NNS
used ||| S:1250 E:1254 ||| VBN
.  ||| S:1254 E:1256 ||| .
Compared  ||| S:1256 E:1265 ||| VBN
with  ||| S:1265 E:1270 ||| IN
patients  ||| S:1270 E:1279 ||| NNS
with  ||| S:1279 E:1284 ||| IN
1  ||| S:1284 E:1286 ||| CD
prescriber ||| S:1286 E:1296 ||| NN
,  ||| S:1296 E:1298 ||| ,
antihypertensive  ||| S:1298 E:1315 ||| JJ
refill  ||| S:1315 E:1322 ||| JJ
adherence  ||| S:1322 E:1332 ||| NN
was  ||| S:1332 E:1336 ||| VBD
lower  ||| S:1336 E:1342 ||| JJR
in  ||| S:1342 E:1345 ||| IN
patients  ||| S:1345 E:1354 ||| NNS
seeing  ||| S:1354 E:1361 ||| VBG
≥4  ||| S:1361 E:1364 ||| CD
prescribers  ||| S:1364 E:1376 ||| NNS
( ||| S:1376 E:1377 ||| -LRB-
odds  ||| S:1377 E:1382 ||| JJ
ratio  ||| S:1382 E:1388 ||| NN
[ ||| S:1388 E:1389 ||| -LRB-
OR ||| S:1389 E:1391 ||| NNP
]  ||| S:1391 E:1393 ||| -RRB-
=  ||| S:1393 E:1395 ||| SYM
0.69 ||| S:1395 E:1399 ||| CD
;  ||| S:1399 E:1401 ||| :
95 ||| S:1401 E:1403 ||| CD
%  ||| S:1403 E:1405 ||| NN
CI  ||| S:1405 E:1408 ||| NNP
=  ||| S:1408 E:1410 ||| SYM
0.59-0.80 ||| S:1410 E:1419 ||| CD
) ||| S:1419 E:1420 ||| -RRB-
,  ||| S:1420 E:1422 ||| ,
but  ||| S:1422 E:1426 ||| CC
the  ||| S:1426 E:1430 ||| DT
number  ||| S:1430 E:1437 ||| NN
of  ||| S:1437 E:1440 ||| IN
cardiometabolic  ||| S:1440 E:1456 ||| JJ
conditions  ||| S:1456 E:1467 ||| NNS
was  ||| S:1467 E:1471 ||| VBD
not  ||| S:1471 E:1475 ||| RB
a  ||| S:1475 E:1477 ||| DT
significant  ||| S:1477 E:1489 ||| JJ
predictor ||| S:1489 E:1498 ||| NN
.  ||| S:1498 E:1500 ||| .
Antidyslipidemia  ||| S:1500 E:1517 ||| JJ
refill  ||| S:1517 E:1524 ||| JJ
adherence  ||| S:1524 E:1534 ||| NN
was  ||| S:1534 E:1538 ||| VBD
lower  ||| S:1538 E:1544 ||| JJR
in  ||| S:1544 E:1547 ||| IN
patients  ||| S:1547 E:1556 ||| NNS
seeing  ||| S:1556 E:1563 ||| VBG
3  ||| S:1563 E:1565 ||| CD
prescribers  ||| S:1565 E:1577 ||| NNS
( ||| S:1577 E:1578 ||| -LRB-
OR  ||| S:1578 E:1581 ||| NNP
=  ||| S:1581 E:1583 ||| SYM
0.80 ||| S:1583 E:1587 ||| CD
;  ||| S:1587 E:1589 ||| :
95 ||| S:1589 E:1591 ||| CD
%  ||| S:1591 E:1593 ||| NN
CI  ||| S:1593 E:1596 ||| NNP
=  ||| S:1596 E:1598 ||| SYM
0.70-0.92 ||| S:1598 E:1607 ||| CD
)  ||| S:1607 E:1609 ||| -RRB-
or  ||| S:1609 E:1612 ||| CC
≥4  ||| S:1612 E:1615 ||| CD
prescribers  ||| S:1615 E:1627 ||| NNS
( ||| S:1627 E:1628 ||| -LRB-
OR  ||| S:1628 E:1631 ||| NNP
=  ||| S:1631 E:1633 ||| SYM
0.77 ||| S:1633 E:1637 ||| CD
;  ||| S:1637 E:1639 ||| :
95 ||| S:1639 E:1641 ||| CD
%  ||| S:1641 E:1643 ||| NN
CI  ||| S:1643 E:1646 ||| NNP
=  ||| S:1646 E:1648 ||| SYM
0.64-0.91 ||| S:1648 E:1657 ||| CD
) ||| S:1657 E:1658 ||| -RRB-
.  ||| S:1658 E:1660 ||| .
Conversely ||| S:1660 E:1670 ||| RB
,  ||| S:1670 E:1672 ||| ,
antidyslipidemia  ||| S:1672 E:1689 ||| JJ
refill  ||| S:1689 E:1696 ||| NNS
adherence  ||| S:1696 E:1706 ||| VBP
improved  ||| S:1706 E:1715 ||| VBN
with  ||| S:1715 E:1720 ||| IN
the  ||| S:1720 E:1724 ||| DT
number  ||| S:1724 E:1731 ||| NN
of  ||| S:1731 E:1734 ||| IN
cardiometabolic  ||| S:1734 E:1750 ||| JJ
conditions ||| S:1750 E:1760 ||| NNS
,  ||| S:1760 E:1762 ||| ,
but  ||| S:1762 E:1766 ||| CC
differences  ||| S:1766 E:1778 ||| NNS
were  ||| S:1778 E:1783 ||| VBD
only  ||| S:1783 E:1788 ||| RB
statistically  ||| S:1788 E:1802 ||| RB
significant  ||| S:1802 E:1814 ||| JJ
for  ||| S:1814 E:1818 ||| IN
≥3  ||| S:1818 E:1821 ||| CD
conditions  ||| S:1821 E:1832 ||| NNS
( ||| S:1832 E:1833 ||| -LRB-
OR  ||| S:1833 E:1836 ||| NNP
=  ||| S:1836 E:1838 ||| SYM
1.31 ||| S:1838 E:1842 ||| CD
;  ||| S:1842 E:1844 ||| :
95 ||| S:1844 E:1846 ||| CD
%  ||| S:1846 E:1848 ||| NN
CI  ||| S:1848 E:1851 ||| NNP
=  ||| S:1851 E:1853 ||| SYM
1.09-1.57 ||| S:1853 E:1862 ||| CD
) ||| S:1862 E:1863 ||| -RRB-
.  ||| S:1863 E:1865 ||| .
In  ||| S:1865 E:1868 ||| IN
multivariate  ||| S:1868 E:1881 ||| JJ
regression  ||| S:1881 E:1892 ||| JJ
models ||| S:1892 E:1898 ||| NNS
,  ||| S:1898 E:1900 ||| ,
the  ||| S:1900 E:1904 ||| DT
number  ||| S:1904 E:1911 ||| NN
of  ||| S:1911 E:1914 ||| IN
conditions  ||| S:1914 E:1925 ||| NNS
and  ||| S:1925 E:1929 ||| CC
number  ||| S:1929 E:1936 ||| NN
of  ||| S:1936 E:1939 ||| IN
prescribers  ||| S:1939 E:1951 ||| NN
were  ||| S:1951 E:1956 ||| VBD
not  ||| S:1956 E:1960 ||| RB
significant  ||| S:1960 E:1972 ||| JJ
predictors  ||| S:1972 E:1983 ||| NN
of  ||| S:1983 E:1986 ||| IN
refill  ||| S:1986 E:1993 ||| JJ
adherence  ||| S:1993 E:2003 ||| NN
in  ||| S:2003 E:2006 ||| IN
the  ||| S:2006 E:2010 ||| DT
group  ||| S:2010 E:2016 ||| NN
of  ||| S:2016 E:2019 ||| IN
patients  ||| S:2019 E:2028 ||| NNS
with  ||| S:2028 E:2033 ||| IN
diabetes ||| S:2033 E:2041 ||| NN
.  ||| S:2041 E:2043 ||| .
Effective  ||| S:2043 E:2053 ||| JJ
management  ||| S:2053 E:2064 ||| NN
of  ||| S:2064 E:2067 ||| IN
care  ||| S:2067 E:2072 ||| NN
and  ||| S:2072 E:2076 ||| CC
medication  ||| S:2076 E:2087 ||| NN
regimens  ||| S:2087 E:2096 ||| NN
for  ||| S:2096 E:2100 ||| IN
complex  ||| S:2100 E:2108 ||| JJ
patients  ||| S:2108 E:2117 ||| NNS
remains  ||| S:2117 E:2125 ||| VBZ
an  ||| S:2125 E:2128 ||| DT
unresolved  ||| S:2128 E:2139 ||| JJ
challenge ||| S:2139 E:2148 ||| NN
,  ||| S:2148 E:2150 ||| ,
but  ||| S:2150 E:2154 ||| CC
these  ||| S:2154 E:2160 ||| DT
results  ||| S:2160 E:2168 ||| NNS
suggest  ||| S:2168 E:2176 ||| VBP
that  ||| S:2176 E:2181 ||| DT
medication  ||| S:2181 E:2192 ||| NN
refill  ||| S:2192 E:2199 ||| NN
adherence  ||| S:2199 E:2209 ||| NNS
might  ||| S:2209 E:2215 ||| MD
be  ||| S:2215 E:2218 ||| VB
improved  ||| S:2218 E:2227 ||| VBN
by  ||| S:2227 E:2230 ||| IN
minimizing  ||| S:2230 E:2241 ||| VBG
the  ||| S:2241 E:2245 ||| DT
number  ||| S:2245 E:2252 ||| NN
of  ||| S:2252 E:2255 ||| IN
prescribers  ||| S:2255 E:2267 ||| VBG
involved  ||| S:2267 E:2276 ||| VBN
in  ||| S:2276 E:2279 ||| IN
a  ||| S:2279 E:2281 ||| DT
patient ||| S:2281 E:2288 ||| NN
's  ||| S:2288 E:2291 ||| POS
care ||| S:2291 E:2295 ||| NN
,  ||| S:2295 E:2297 ||| ,
at  ||| S:2297 E:2300 ||| IN
least  ||| S:2300 E:2306 ||| JJS
for  ||| S:2306 E:2310 ||| IN
hypertension  ||| S:2310 E:2323 ||| NN
and  ||| S:2323 E:2327 ||| CC
dyslipidemia ||| S:2327 E:2339 ||| NN
.  ||| S:2339 E:2341 ||| .
